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Crohn‟s disease is an auto-immune disease characterized 
by an exaggerated Th1- mediated immune response that 
affects any part of the gastrointestinal tract from the mouth 
to the anus. Symptoms include diarrhea, abdominal pain, 
and weight loss. Although thalidomide exhibits anti-
inflammatory properties useful for the treatment of 
Crohn‟s disease, it presents several harmful side effects 
such as fatigue, drowsiness and constipation.
1
 Hence, 
appropriate delivery systems should be used in order to 
limit the side effects associated with thalidomide. In this 
study, we examine the potential of APA microcapsules 
containing thalidomide in reducing intestinal inflammation 
both in-vitro and in-vivo. LPS-activated RAW 264.7 
mouse macrophage cells are commonly used to mimic 
intestinal inflammation. 
2, 3
 LPS-induced inflammation is 
characterized by an increase in inflammatory cytokines, 
and other crucial mediators of inflammation such as nitric 
oxide (NO). 
4, 5 
The inflammatory cytokines investigated in 
the present study are TNF-α, IL-6 and IL-1β. TNF-α is a 
pro-inflammatory cytokine that plays a major role in the 
inflammation related to Crohn‟s disease.6 In addition, acute 
inflammation is characterized by an increased level of IL-
1β leading to cell or tissue damage.7 Finally, IL-6 is a 
critical pro-inflammatory cytokine that is a primordial 
mediator of chemokine production and leukocyte 
apoptosis. 
8
 An animal model of intestinal inflammation is 
also used to mimic Crohn‟s disease. The model is based on 
the intrarectal administration of TNBS to Balb/c mice. 
This chemically-induced model has shown to trigger an 




MATERIAL AND METHODS 
Chemicals and laboratory equipment 
The Research IER-20 cell encapsulator was purchased 
from Inotech Biosystems International. The chemicals 
thalidomide, alginic acid, poly–L-lysine (hydrobromide) 
and dimethyl sulfoxide were purchased by Sigma-Aldrich 
Canada. The MTS Reagent Powder was purchased from 
Promega. Cells were incubated in a Sanyo MCO-18M 
Oxygen/Carbon Dioxide Incubator and stored in a Sanyo 
MDF-U50V -86 degrees Celsius Freezer, supplied by 
SANYO Canada. A Lomo Biological Inverted Microscope 
BIOLAMP, supplied by LOMO America, was used for 
microscopic cellular observations. ELISA testing was done 
on Mouse ELISA Ready-SET-Go! supplied by 
eBioscience. A Nitric Oxide Colorimetric Assay Kit from 
Biovision was used for calculating the amount of nitric 
oxide in cell supernatants. A Bio-Tek uQuant Universal 
Microplate Spectrophotometer from Fisher Scientific was 
used for ELISA plate analysis. Finally, cell centrifugation 
was performed on a NAPCO 2028R Centrifuge, supplied 
by Precision. 
 
Preparation of APA microcapsules containing 
thalidomide 
Alginic acid was added to deionized water to make a 1.5% 
alginate solution. (±)- Thalidomide ((±)-2-(2,6-Dioxo-3-
piperidinyl)-1H-isoindole-1,3(2H)-dione) was dissolved in 
deionized water at a concentration of 0.035 mg/ml by 
stirring and heating for 24 hours and added to the alginate 
solution. Alginic acid was additionally added to maintain a 
1.5% concentration. APA beads were then formed by 
running the above solution through an Inotech 
encapsulator pump using a 300 μm nozzle. Frequency was 
set to 528 Hz, flow rate to 20.8 ml/min and voltage to 1.48 
kV. Formed beads were collected in a prepared 0.1M 
calcium chloride solution to avoid cell aggregation. The 
beads were then washed with deionized water and soaked 
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in a 0.1% poly-l-lysine bath for 10 minutes. Beads were 
washed again and soaked in 0.15% alginate solution for 15 
minutes. Final washing was done with water and beads 
were transferred into calcium chloride for storage. The 
capsules were visually evaluated for uniformity and 
integrity through a Lomo light microscope with 200X 
magnification. 
Macrophage cell culturing 
Mouse RAW 264.7 macrophage cells were purchased from 
the American Type Culture Collection (ATCC) and 
cultured according to standard procedures using 
Dulbecco‟s Modified Eagles‟s Medium (DMEM). The 
cells were incubated in a 37  Celsius and 5% CO2 
environment in a Sanyo MCO-18M Oxygen/Carbon 
Dioxide incubator. 
 
Cell viability assay 
The aim of this study is to evaluate the effect of 
microencapsulated thalidomide on cell viability. 
Mitochondrial reduction of MTS into aqueous soluble 
formazan was used as an indicator of cell viability. 
10, 11
 
The cells were cultured in a 96-well plate at a 
concentration of 5 × 104 cells/well. The plate was 
incubated for 24 hours at 37°C in a humidified, 5% CO2 
atmosphere. After aspirating the culture media, the wells 
were separately treated with empty APA microcapsules, 
APA microcapsules containing thalidomide (0.1g), 
thalidomide (0.7 mg/ml) and LPS (10 μg/ml). A control 
group consisting of no treatment was also included in the 
study. After incubating the plate for 24 hours at 37°C in a 
humidified, 5% CO2 atmosphere, the cells were 
resuspended in 100 μL medium and cell viability was 
analyzed by MTS assay. Procedures were performed as 
described by the manufacturer‟s protocol. Briefly, 20 μL of 
MTS/PMS solution was added to 100 μL of culture 
medium. After incubating the plate for 1 hour at 37 
degrees in a humidified, 5% CO2 atmosphere, the 
absorbance was read at 490 nm using an ELISA plate 
reader. The amount of formazan product measured 
spectrophotometrically is directly proportional to the 
number of living cells in culture. The percentage cell 
viability is illustrated in Figure 1. 
 
 
Figure 1: Effect of LPS (10 μg/ml), empty microcapsules, microencapsulated thalidomide (0.7 mg/ml) and thalidomide 
(0.7 mg/ml) on RAW 264.7  cell viability. Each column represents the percentage cell viability compared to the control 
group. Values are expressed as the mean + S.D. 
Induction of inflammatory cytokines by LPS 
Lipopolysacharide (LPS) was used to stimulate RAW 
264.7 macrophage cells. It was shown that a concentration 
of 10 μg/ml of LPS can significantly induce the 
macrophage cells to produce more pro-inflammatory 
cytokines such as TNF-α12, 13. 0.25 ml of media solution 
containing 380 000 RAW 264.7 cells were added to 0.25 
ml of LPS (10 μg/ml) within a Falcon Brand 24-well Flat 
Bottom Tissue Culture Plate. The experiment was divided 
into four different groups. The first group consisted of 
cells treated with LPS alone. The second group consisted 
of cells treated with LPS and 0.15 g of APA microcapsules 
containing thalidomide solution (0.7 mg/ml). In the third 
group, 0.15 g of empty microcapsules was added to LPS-
induced cells. The last group consisted of cells treated with 
LPS and free thalidomide in solution (0.7 mg/ml). The 
amount of inflammatory cytokines and nitric oxide was 
then measured from cell supernatant collected at five 
separate time points: 0h, 1h, 3h, 9h, 16h, 24h and 48h, 
after incubation in a standard 5% CO2 environment, at 37 
degree. 
Cytokine production in cell supernatant 
The amount of inflammatory cytokines produced in cell 
supernatant was measured using commercially available 
ELISA Kit for TNF-α, IL-6 and IL-1β. Briefly, replicate 
serial dilutions of the antigen standard and experimental 
samples were prepared. 50 μl of Assay Buffer was then 
added into each well of the 8-well ELISA strips. After 
transferring 50 μl of samples and standards to the 
appropriate wells, the plate was gently shaken for 10 
seconds and allowed to incubate for 2 hours at room 
temperature. The ELISA plate was then manually washed 
with 1x washing buffer. This process was repeated twice. 
Then, 100 μl of Detection Antibody solution was added to 
each well. After incubating the plate for 1 hour at room 
temperature, the ELISA wells were washed again as 
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described above. 100 μl of Avidin-HRP solution was then 
added to all wells, and the plate was incubated for 30 
minutes at room temperature. After 4 washing steps, 100 
μl of Development Solution was added to each well and 
the plate was incubated for 15 min at room temperature, in 
the dark. Finally, 100 μl of Stop solution was added and 
the absorbance was read at 450 nm and 570 nm. 
Measurement of nitric oxide from cell supernatant 
NO production was assayed by measuring nitrite (a stable 
degradation product of NO) in supernatant of cultured 
RAW 264.7 cells. 
14
 Nitric oxide plays a crucial role in 
inflammation and can be measured from cell supernatant. 
15, 16
 Nitric Oxide Colorimetric Assay was performed as 
described by the manufacter's protocol. 5 μl of the Nitrate 
Reductase mixture and enzyme cofactor was added to each 
well containing cell supernatant diluted in Assay buffer. 
The plate was then covered and incubated at room 
temperature for 1h in order to convert nitrate to nitrite. The 
enhancer (5 μL) was then added to each well and was let 
incubated for 10 min. The last step uses Griess reagents to 
convert nitrite to a deep purple azo-compound. The 
absorbance was read at 540 nm using an ELISA plate 
reader. 
Induction of inflammation using TNBS 
Male Balb/c mice, 6 weeks old and weighing 23-26 g, 
were purchased from The Jackson Laboratory (Bar Harbor, 
ME) and housed in the Lyman Duff animal center of 
Mcgill University. TNBS (120 mg/kg/bodyweight) 
dissolved in 30% ethanol 
10, 17 
was used to induce intestinal 
inflammation in this strain of mice. This is a well-
characterized model that has been shown to resemble 
human Crohn‟s disease.10 The technique involves the use 
of a rubber catheter inserted 3-4 cm via the anus.18 Prior 
to TNBS injection, the mice were slightly anesthetized 
with isoflurane gas. The mice were then kept in vertical 
position for 30s to prevent leakage of TNBS. After TNBS 
injection, the mice were monitored daily for survival and 
body mass. All animals were cared for in accord with the 
Canadian Council on Animal Care (CCAC) guidelines. 
 
Treatment protocol 
The animal use protocol was approved by the Animal Care 
Committee of McGill University. In order to investigate 
the therapeutic effects of APA microcapsules containing 
thalidomide, mice were divided randomly into five groups. 
Control group (n=5, receiving 30% ethanol only and no 
treatment) and TNBS group (n=5, receiving TNBS and no 
treatment) were included in this study. The treated mice 
were divided into three distinct groups (n=10) that consist 
of daily gavaging the animals with empty APA 
microcapsules, APA microcapsules containing thalidomide 
(100 mg/kg/bodyweight) and thalidomide (100 
mg/kg/bodyweight) for two weeks five days following 
TNBS injection. 
 
Assessment of inflammatory markers 
In order to investigate the therapeutic effects of 
microencapsulated thalidomide, the level of TNF-α, IL-6, 
IL-1β and NO was measured from blood samples. These 
cytokines participate in the inflammation associated with 
Crohn‟s disease.19, 20 Blood sample was collected from 
mice at weekly interval via the tail vein. The serum was 
then separated from the blood sample by centrifugation at 
36,000 rpm for 8 min. The concentration of pro-
inflammatory cytokines was measured in serum using 
ELISA analysis (eBioscience) and the level of NO was 
quantified using Nitric Oxide Colorimetric Assay 
(Biovision). 
Statistical analysis 
Values are expressed as mean ± SD. Study was considered 
a randomized balanced design. Statistical comparisons 
between various biomarkers were carried out by repeated 
measures analysis of variance (ANOVA). Statistical 
comparisons between various treatment groups were 
carried out by using the general linear model (GLM). 
Statistical significance was set at p < 0.05. 
 
RESULTS AND DISCUSSION 
Cell viability assay 
Experiments were designed to determine the non-
cytotoxicity effect of microencapsulated thalidomide.  
 
 
Figure 2: Comparison photomicrographs of RAW 264.7 
macrophage cells treated for 24 hours at 37°C with: (A) 
Control group, (B) Empty microcapsules, (C) 
Microencapsulated thalidomide (0.7 mg/ml), (D) 
Thalidomide solution (0.7 mg/ml) and (E) LPS (10 μg/ml). 
 
MTS assay clearly suggests that the viability of RAW 
264.7 macrophage cells remains intact after treating with 
APA microcapsules containing Thalidomide at a 
concentration of 0.7 mg/ml. As illustrated in Figure 1, the 
percentage viability of macrophage cells compared to the 
control group was 98.43 ± 0.79 %, 99.11 ± 0.36%, 98.99 ± 
Fakhoury et al                              Journal of Drug Delivery & Therapeutics; 2013, 3(5), 11-17    14 
© 2011, JDDT. All Rights Reserved                                             ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
 
0.5 % and 98.55 ± 0.67 % after treating with empty APA 
microcapsules, microencapsulated thalidomide, free 
thalidomide and LPS respectively. Cells were then 
observed in the microscope under x200 magnification and 
no cell damage was observed (Figure 2). The RAW 264.7 
macrophage cells retained their ability to proliferate in 
Dulbecco's modified Eagle's medium while maintaining 
identical shape. 
 
Cytokine production in cell supernatant 
The amount of pro-inflammatory cytokines TNF-α, IL-6 
and IL-1β was measured from the supernatant after 
incubation of cells with 10 μg/ml of LPS. In the LPS 
control group, the initial concentration of TNF-α, IL-1β 
and IL-6 was 238.3 ± 5.8 pg/ml, 4.3 ± 0.1 pg/ml and 235 ± 
10 pg/ml respectively. Activating RAW 264.7 cells with 
LPS significantly increased the production of pro-
inflammatory cytokines. After 48h of incubation in LPS, 
the levels of TNF-α, IL-1β and IL-6 in cell supernatant 
reached a concentration of 911.7 ± 35.1 pg/ml, 10.2 ± 0.1 
pg/ml and 451.7 ± 30.6 pg/ml respectively. Treating the 
cells with empty APA microcapsules did not significantly 
alter the expression profile of these inflammatory 
cytokines. However, free thalidomide was able to suppress 
the production of TNF-α, IL-1β and IL-6 immediately 3h 
following LPS induction. A delayed inhibition of cytokine 
production was observed when treating the cells with APA 
microcapsules containing thalidomide. The concentration 
of TNF-α, IL- 1β and IL-6 measured after 9h of incubation 
with microencapsulated thalidomide was 625 ± 26.5 pg/ml, 
8.13 ± 0.21 pg/ml and 345 ± 10 pg/ml respectively. 
However, after 48 hours of incubation, the concentration 
of TNF-α, IL-1β and IL-6 decreased to 415 ± 65.6, 5.4 ± 




Figure 3: Effect of empty microcapsules, microencapsulated thalidomide (0.7 mg/ml) and thalidomide (0.7 mg/ml) on 
TNF-α concentration in cell supernatant from RAW 264.7 macrophage cells stimulated with 10 μg/ml of LPS. 
Comparisons were made after incubation times of 0, 1, 3, 9, 16, 24 and 48 hours. Values are expressed as the mean + S.D. 
of three independent experiments. 
 
Figure 4: Effect of empty microcapsules, microencapsulated thalidomide (0.7 mg/ml) and thalidomide (0.7 mg/ml) on IL-
1β concentration in cell supernatant from RAW 264.7 macrophage cells stimulated with 10 μg/ml of LPS. Comparisons 
were made after incubation times of 0, 1, 3, 9, 16, 24 and 48 hours. Values are expressed as the mean + S.D. of three 
independent experiments. 
Fakhoury et al                              Journal of Drug Delivery & Therapeutics; 2013, 3(5), 11-17    15 
© 2011, JDDT. All Rights Reserved                                             ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
 
 
Figure 5: Effect of empty microcapsules, microencapsulated thalidomide (0.7 mg/ml) and thalidomide (0.7 mg/ml) on IL-6 
concentration in cell supernatant from RAW 264.7 macrophage cells stimulated with 10 μg/ml of LPS. Comparisons were 
made after incubation times of 0, 1, 3, 9, 16, 24 and 48 hours. Values are expressed as the mean + S.D. of three 
independent experiments. 
Nitric oxide production in cell supernatant 
The concentration of nitric oxide in cell supernatant was 
measured to assess the extent of inflammation. Figure 6 
illustrates the level of nitric oxide released after 
stimulation of RAW 264.7 macrophage cells with 
Lipopolysaccharides (LPS). It was shown that treating the 
cells with LPS alone (control group) for 48h increased the 
concentration of NO from 1.5 ± 0.2 μM to 42.6 ± 0.6 μM. 
Treating the LPS-activated cells with empty APA 
microcapsules did not significantly alter the production of 
NO compared to the control group. However, 
microencapsulated thalidomide and free thalidomide (0.7 
mg/ml) lowered the concentration of NO to 25.9 ± 0.6 μM 
to 22.6 ± 0.7 μM respectively after 48h of incubation. 
 
Figure 6: Effect of empty microcapsules, microencapsulated thalidomide (0.7 mg/ml) and thalidomide (0.7 mg/ml) on 
nitrite production from RAW 264.7 macrophage cells stimulated with 10 μg/ml of LPS. Comparisons were made after 
incubation times of 0, 1, 3, 9, 16, 24 and 48 hours. Values are expressed as the mean + S.D. of three independent 
experiments. 
 
TNF-α, IL-6 and IL-1β level in serum   
The concentration of TNF-α, IL-6 and IL-1β is measured 
in blood serum from Balb/c mice following TNBS 
administration (Figure 7). ELISA analysis of cytokine 
levels confirmed that experimental mice treated with 
TNBS have a higher level of TNF-α, IL-6 and IL-1β 
compared to the control group. It was shown that APA 
microcapsules containing thalidomide (100 
mg/kg/bodyweight) caused a marked decreased in the level 
of pro-inflammatory cytokines. Treating the mice with 
empty microcapsules did not alter the concentration of 
cytokines following TNBS administration. Moreover, 
using APA microcapsules as a delivery carrier for 
thalidomide have proven to be much more successful in 
Fakhoury et al                              Journal of Drug Delivery & Therapeutics; 2013, 3(5), 11-17    16 
© 2011, JDDT. All Rights Reserved                                             ISSN: 2250-1177                                                   CODEN (USA): JDDTAO 
 
lowering TNF-α, IL-6 and IL-1β compared to free 
thalidomide. Treating the 60 mice with thalidomide (100 
mg/kg/bodyweight) for a period of two weeks decreased 
the level of TNF-α, IL-6 and IL-1β from 2557.1 ± 22.5 
pg/ml, 7561.8 ± 103.4 pg/ml, 2388.4 ± 64.2 pg/ml to 
1295.8 ± 34.1 pg/ml, 2852.5 ± 90.6 pg/ml and 1084.2 ± 
38.6 pg/ml respectively. However, treating the mice with 
microencapsulated thalidomide (100 mg/kg/bodyweight) 
for two weeks decreased the level of TNF-α, IL-6 and IL-
1β to 803.25 ± 44.9 pg/ml, 1883 ± 124.9 pg/ml and 1165.5 
± 31.3 pg/ml respectively. 
 
Figure 7: Effect of empty microcapsules, 
microencapsulated thalidomide (100 mg/kg/bodyweight) 
and thalidomide (100 mg/kg/bodyweight) on serum IL-6, 
IL-1β and TNF-α level following TNBS injection in Balb/c 
mice. The level of cytokines in the serum was measured 
after two-weeks treatment. Values are shown as mean + 
S.D. of mice for each group. 
CONCLUSION 
Results demonstrate that APA microcapsules containing 
thalidomide exert inhibitory effects on the secretion of NO, 
TNF-α, IL-6 and IL-1β from RAW 264.7 cell supernatant. 
The latter inflammatory markers are key mediators of host 
defense and inflammatory response associated with 
Crohn's disease. 
21, 22
 Moreover, it was shown that treating 
the cells with microencapsulated thalidomide resulted in a 
delayed inhibition of inflammatory markers of several 
hours compared to the cells treated with thalidomide alone. 
This suggests that APA membrane enables a slow release 
of thalidomide, thus increasing total delivery time. This 
important characteristic of APA microcapsule could be 
useful in the treatment of Crohn's disease where local 
delivery of the encapsulated drug to affected sites of the 
gastrointestinal tract is needed.
23
 Furthermore, results 
demonstrate that treating the cells with empty APA 
microcapsules, APA microcapsules containing 
thalidomide, thalidomide solution (0.7mg/ml) and LPS (10 
μg/ml) did not affect cell viability. Cell still maintain their 
ability to grow and proliferate in culture and the 
percentage of viable cells observed after 24h of incubation 
with the treatment was close to 100%. However, it was 
shown that treating RAW 264.7 cells with LPS at a 
concentration of 10 μg/ml caused a change in cell 
morphology and size. More specifically, the majority of 
the macrophage cells lost their circular shape and became 
more elongated after stimulation with LPS. Overall the 
results showed that artificial cell containing thalidomide 
could significantly suppress the formation of NO, TNF-α, 
IL-6 and IL-1β from RAW 264.7 cell supernatant after 
LPS stimulation. MTS assay confirmed the fact that 
treating the cells with APA microcapsules containing 
thalidomide does not affect their viability and ability to 
grow in cultured medium. Indeed, this characteristic of 
APA microcapsules makes it an ideal carrier for 
thalidomide delivery since the proposed therapy can 
significantly lower the production of pro-inflammatory 
cytokines while preserving the intestinal tract integrity. 
Our results also provide the in-vivo evidence that 
microencapsulated thalidomide exert anti-inflammatory 
properties using a murine model of Crohn‟s disease. 
Following induction of intestinal inflammation by TNBS 
injection, the level of pro- inflammatory cytokines TNF-α, 
IL-1β and IL-6 in blood serum significantly increased. 
Treating the mice with APA microcapsules containing 
thalidomide caused a marked decrease in the level of TNF-
α, IL-1β and IL-6. Understanding the inhibitory effect of 
artificial cells containing thalidomide in the production of 
inflammatory markers from macrophage cells will help 
contribute to the development of novel therapies for 
Crohn's disease and other immune-mediated disorders. 
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